EV-BM-MSC/TERT2922022-10-07T07:47:35+00:00

Extracellular vesicles
from bone marrow-derived MSCs

Extracellular vesicles (EVs) play an essential role in cellular communication by transporting proteins, lipids as well as nucleic acids. EVs from our bone marrow-derived mesenchymal stromal cell line BM-MSC/TERT292 are characterized by the typical EV morphology, presence of EV marker proteins as well as anti-inflammatory and anti-fibrotic activities.

General information

Cat#: EV-CHT-063-0292-A1 (5 x 10^9 EVs in 150 µl) | EV-CHT-063-0292-A2 (1 x 10^10 EVs in 300 µl)

Origin/cell factory: human bone marrow-derived MSCs (Cat# CHT-063-0292)
Enrichment/storage medium: tangential flow filtration, 20 mM HEPES
Characteristics:
100-200 nm, 34.8 µg/µl of proteins (1 x 10^9 EVs), sterile
Application:
research&development, not for clinical use

Presence of typical EV surface marker proteins

EVs derived from BM-MSC/TERT292 cells carry typical surface proteins such as CD81, CD9 and CD63 as demonstrated using CD81+ bead-based flow cytometry. Delta mean fluorescence intensity (DMFI) was calculated by normalizing to MFI of control beads.

Anti-inflammatory activity of extracellular vesicles from

BM-MSC/TERT292

Treatment of mouse macrophage cells (RAW264.7) with lipopolysaccharide (LPS) induces the formation of nitric oxide (NO) indicating an inflammatory reaction. Addition of the positive control Dexamethasone (Dexa) significantly reduces NO secretion.

Similarly, addition of EVs derived from BM-MSC/TERT292 cells significantly reduces NO formation indicating an anti-inflammatory activity of the EVs.

Anti-fibrotic activity of extracellular vesicles from

BM-MSC/TERT292

Treatment of human fibroblasts (fHDF/TERT166) with Transforming Growth Factor beta (TGF-ß1) induces the expression of alpha smooth muscle actin (α-SMA) indicating myofibroblast differentiation/activation, which is a key event in physiological and pathological tissue repair.

Addition of EVs derived from BM-MSC/TERT292 cells significantly reduces α-SMA induction, indicating an anti-fibrotic activity of the EVs.

PP2, a Src-kinase inhibitor, is used as positive control.

FAQs

Can we use the extracellular vesicles for clinical application?2022-02-18T17:26:36+00:00

No, the EVs cannot be used in humans. However, Evercyte EV production cell lines such as ASC/TERT300 or P-MSC/TERT308 qualify for production of clinical grade material. Please contact us for more detailed information on the quality of our EV cell factories.

Can I use the the exosomes/extracelluar vesicles for sensitive cell cultures?2021-06-21T07:39:12+00:00

Yes. Our exosomes/extracelluar vesicles do not carry contaminations (bacteria incl. mycoplasma, fungi) or endotoxins and have been tested for their activity on primary like cells.

Upon arrival immediately transfer the product to -80°C.

Store product at -80°C (for up to 6 months) until use.

Thaw the EVs on ice, centrifuge before opening the tube to ensure that the solution is collected at the bottom of the tube. Then, mix carefully by pipetting up and down and aliquot for further use to avoid multiple freeze thaw cycles.

Store the aliquots at -80°C until use.

After thawing, store the EVs at 4°C for a maximum of 1 day.

Product data sheet – certificate of analysis

Product data sheet (PDS) download
Certificate of analysis
is available upon request | Please contact us indicating the respective LOT numbers

Data on Markers and Functions

Anti-inflammatory activity of EVs derived from BM-MSC/TERT292
Presence of typical EV marker proteins
Anti-fibrotic activity of EVs from BM-MSC/TERT292 cells

Applications

Development of new anti-inflammatory approaches
Development of a new therapy for the treatment of COVID-19

Selected publications: exosomes for the treatment of COVID-19

Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. (2020) Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 2020 Jun 15;29(12):747-754. https://pubmed.ncbi.nlm.nih.gov/32425691/

Verena Börger V, Weiss DJ, Anderson JD, Borràs FE, Bussolati B, Carter DRF, Dominici M, Falcón-Pérez JM, Gimona M, Hill AF, Hoffman AM, de Kleijn D, Levine BL, Lim R, Lötvall J, Mitsialis SA, Monguió-Tortajada M, Muraca M, Nieuwland R, Nowocin A, O’Driscoll L, Ortiz LA, Phinney DG, Reischl I, Rohde E, Sanzenbacher R, Théry C, Toh WS, Witwer KW, Lim SK, Giebel B. (2020) International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19. Cytotherapy. 22(9):482-485. https://pubmed.ncbi.nlm.nih.gov/32425691/

Selected publications: exosomes for the treatment of wounds

Casado-Díaz A, Quesada-Gómez JM, Dorado G. (2020) Extracellular Vesicles Derived From Mesenchymal Stem Cells (MSC) in Regenerative Medicine: Applications in Skin Wound Healing. Front Bioeng Biotechnol. 8:146. https://pubmed.ncbi.nlm.nih.gov/32195233/

Print Friendly, PDF & Email

EV-BM-MSC/TERT292

5 x 10^9 particles/150 µl – € 1.875,-

SPECIAL OFFER:

40% introductory discount

Ordering now

Related Products

Bone marrow-derived mesenchymal stromal cells

BM-MSC/TERT292

read more

Related Services

Enrichment and characterization of EVs from your cell culture supernatant

send us a request

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

Related Products

adipose-derived mesenchymal stem cells

ASC/TERT300

Related Services

Production and characterization of extracellular vesicles

specific request

Customer Reviews

“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”

 

Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.

“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform.  We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”

Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.

Print Friendly, PDF & Email

from

€ 1.875

EV-ASC/TERT300
Cat#: EV-001-0300-A2

Ordering

Title

Go to Top